OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Heart Failure is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	1093
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci	750
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology	231
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial	211
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and	208
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial	197
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications	182
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology	182
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019	158
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy	123
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study	119
Ultrasound imaging of congestion in heart failure: examinations beyond the heart	112
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan	110
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients	107
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care	106
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)	106
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper	105
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure	104
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA)	104
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study	103
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction	103
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF	100
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis	97
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure	92
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial	92

Cachexia, muscle wasting, and frailty in cardiovascular disease	88
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection	85
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies	83
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC	83
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction	82
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy	81
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review	81
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction	81
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review	80
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart	79
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction	79
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization	78
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades	76
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction	76
The cancer patient and cardiology	75
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist	74
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients	73
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology	71
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje	70
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology	70
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men	69
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial	69
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy	68
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu	68
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics	68
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study	67
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	66
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure	65
Effect of dapagliflozin on anaemia in DAPA‐HF	64
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF	61
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology	61
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr	56
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey	56
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study	55
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and r	54
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality	54
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction	53
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial	52
One‐year results of the first‐in‐man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study	52
In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network	51
Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis	49
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry	48
Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata	48
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology	47
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the Eu	47
Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis	46
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm A	45
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials	45
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index	44
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system	44

Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP: A clinical consensus statement from the Heart Failure Association of the ESC	44
Use of biomarkers to diagnose and manage cardiac amyloidosis	44
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF	44
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study	44
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy	43
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study	43
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience	43
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care	43
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure	42
Urinary peptides in heart failure: a link to molecular pathophysiology	42
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry	42
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis	42
The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic	42
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients	41
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure	41
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of th	41
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis	41
The HFA‐PEFF and H₂FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction	41
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation:1‐yearresults from theCHOICE‐MIregistry	40
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced	40
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?	40
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction	39
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations	39
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial	39
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhib	39
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial	39
Worsening renal function in acute heart failure in the context of diuretic response	39
Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of A	39
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry	38
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity	38
Epicardial fat in heart failure with reduced versus preserved ejection fraction	38
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score	37
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial	37
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	37
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF	37
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology	37
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis	37
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease	37
Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives	37
Sex and central obesity in heart failure with preserved ejection fraction	37
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID‐19 infection	36
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of	36
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure	36
The significance of left ventricular ejection time in heart failure with reduced ejection fraction	36
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) tri	36
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment	36
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the	36
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis	36
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI	36
Head‐to‐head comparison of contemporary heart failure risk scores	35
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF	35
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial	35
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis	35
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials	35
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map	35
Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand	34
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	34
Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction	34
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction	33
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction	33
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea	33
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial	33
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial	33
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire	33
Systemic embolism in amyloid transthyretin cardiomyopathy	33
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	33
Practical outpatient management of worsening chronic heart failure	33
Value of the HFA‐PEFF and H₂FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis	32
Atrial amyloidosis: mechanisms and clinical manifestations	32
Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction	31
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction	31
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand	30
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort	30
Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA‐VO₂): a randomized clinical trial	30
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock	30
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR<	30
Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis	29
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial	29
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis	29
High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND	28

In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable	28
Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	28
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium	28
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia	28
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial	28
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial	28
Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial	28
Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction	27
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiolo	27
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk	27
A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta‐analysis	27
Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis	27
Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry	27
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial	27
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controll	26
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary	26
Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC	26
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials	26
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study	26
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study):	26
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study	26
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction	26
Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice	26
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA‐MODA study	26
Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world	25
Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from th	25
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	25
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF	25
The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative	25
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro	25
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure	25
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	25
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction	25
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis	25
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial	24
Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC‐HFA Heart Failu	24
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans	24
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	24
Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings	24
Clinical characteristics and 1‐year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database‐Heart F	23
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	23
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	23
Artificial intelligence and heart failure: A state‐of‐the‐art review	23
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure	23
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results fr	23
Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure	23
Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry	22
N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis	22
Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology	22
Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study	22
Change in ejection fraction and long‐term mortality in adults referred for echocardiography	22
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	22
Transient versus persistent improved ejection fraction in non‐ischaemic dilated cardiomyopathy	22
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	22
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF	22
Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non‐randomized, open‐label, proof‐of‐concept study	22
Advanced cancer is also a heart failure syndrome: a hypothesis	22
Effects of haemodynamically atrio‐ventricular optimized His bundle pacing on heart failure symptoms and exercise capacity: the His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) ran	22
Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan	22
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics	22
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial	21
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF	21
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR‐Preserved trial	21
Clinical inertia and medical therapy for heart failure: the unintended harms of ‘first, do no harm’	21
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF	21
Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure	21
Effects of remote haemodynamic‐guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS‐HF study	21
Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction	21
Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry	21
A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction	21
Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications	21
Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction	21
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: apost‐hocanalysis of theATHENAtrial	21
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone	20
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology	20
Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models	20
Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the	20
Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry analysi	20
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial	20
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	20
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis	20
Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines	20
Relationship between body mass index, cardiovascular biomarkers and incident heart failure	20
Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC	19
Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry	19
Sex‐specific analysis of the rapid up‐titration of guideline‐directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG‐HF trial	19
Evolution of tricuspid regurgitation after transcatheter edge‐to‐edge mitral valve repair for secondary mitral regurgitation and its impact on mortality	19
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	19
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	19
Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED‐HF	19
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced	19
Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers	19
Insulin resistance and incident heart failure: a meta‐analysis	19
Post‐discharge arrhythmic risk stratification of patients with acute myocarditis and life‐threatening ventricular tachyarrhythmias	19
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial	19